Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Accelerate Diagnostics's Days Sales Outstanding or its related term are showing as below:
MEX:AXDX's Days Sales Outstanding is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 64.94 * Ranked among companies with meaningful Days Sales Outstanding only.
Accelerate Diagnostics's Days Sales Outstanding
declined
from Dec. 2023 (80.76) to Dec. 2024 (64.01).
Accelerate Diagnostics (MEX:AXDX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Accelerate Diagnostics Days Sales Outstanding Related Terms
Accelerate Diagnostics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Accelerate Diagnostics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics Days Sales Outstanding Chart
MEX:AXDX vs MSIU, BIOLQ, AFIB: Days Sales Outstanding Comparison
For the Medical Devices subindustry, Accelerate Diagnostics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accelerate Diagnostics Days Sales Outstanding vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Accelerate Diagnostics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Accelerate Diagnostics's Days Sales Outstanding falls into.
Accelerate Diagnostics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accelerate Diagnostics (MEX:AXDX) has a Days Sales Outstanding of 64.01 as of Dec. 2024. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Accelerate Diagnostics and its competitors.
Is Accelerate Diagnostics' Days Sales Outstanding too high?
Accelerate Diagnostics' current Days Sales Outstanding is 64.01. The Medical Devices & Instruments industry median Days Sales Outstanding is 64.94. Accelerate Diagnostics' value of 64.01 is 1.4% below this industry median. Overall, Accelerate Diagnostics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Accelerate Diagnostics' Days Sales Outstanding compare to MSIU and BIOLQ?
Accelerate Diagnostics' Days Sales Outstanding of 64.01 can be compared against companies in the Medical Devices & Instruments industry. The industry median Days Sales Outstanding is 64.94. Accelerate Diagnostics' value of 64.01 is 1.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Devices & Instruments company?
The median Days Sales Outstanding among Medical Devices & Instruments companies is 64.94, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accelerate Diagnostics's current Days Sales Outstanding of 64.01 is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Accelerate Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median Days Sales Outstanding is 64.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accelerate Diagnostics's current Days Sales Outstanding is 64.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accelerate Diagnostics stock overvalued right now?
Accelerate Diagnostics (MEX:AXDX) has a current Days Sales Outstanding of 64.01. The current Days Sales Outstanding is 64.01 and 1.4% below the Medical Devices & Instruments industry median of 64.94. Accelerate Diagnostics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Accelerate Diagnostics (MEX:AXDX), the current Days Sales Outstanding is 64.01 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accelerate Diagnostics Inc is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Its Clinical Microbiology products include Accelerate Pheno system, Accelerate PhenoTest BC Kit, and Accelerate Arc module & BC kit. The company earns the majority of its revenue from the domestic market. The group operates as one operating segment, deriving instrument, consumable, and service revenues from customers engaged in healthcare diagnostics within the United States. Product revenue is derived from the sale or rental of instruments and sales of related consumable products. Service revenue is derived from the sale of extended service agreements.
12GF Score
Get the complete analysis for MEX:AXDX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:AXDX has been successfully added to your 
